Palatin Technologies, Inc. (PTN) |
|
1.51 0.01 (0.67%)
|
09-29 15:59 |
|
Open: |
1.45 |
Pre. Close: |
1.5 |
|
High:
|
1.5619 |
Low:
|
1.45 |
|
Volume:
|
118,294 |
Market Cap:
|
17(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:29:51 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.44 One year: 2.92 |
| Support: |
Support1: 1.42 Support2: 1.18 |
| Resistance: |
Resistance1: 2.09 Resistance2: 2.5 |
| Pivot: |
1.72  |
| Moving Average: |
MA(5): 1.52 MA(20): 1.84
MA(100): 2.17 MA(250): 3.02 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 14.6 %D(3): 13.3 |
| RSI: |
RSI(14): 35.2 |
| 52-week: |
High: 6.4 Low: 1.42 |
| Average Vol(K): |
3-Month: 94 (K) 10-Days: 94 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTN ] has closed above bottom band by 25.1%. Bollinger Bands are 44.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.56 - 1.57 |
1.57 - 1.58 |
|
Low:
|
1.43 - 1.44 |
1.44 - 1.45 |
|
Close:
|
1.5 - 1.51 |
1.51 - 1.52 |
|
Company Description |
|
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. |
Headline News |
Thu, 28 Sep 2023
JAZZ: 3 Biotech Stocks to Buy Instead of Palatin Technologies (PTN) - StockNews.com
Thu, 28 Sep 2023
Earnings Flash (PTN) PALATIN TECHNOLOGIES Posts Q4 ... - Marketscreener.com
Thu, 28 Sep 2023
Palatin Technologies Reports Mixed Financial Results for Q4 and ... - Best Stocks
Thu, 28 Sep 2023
Palatin Technologies Inc. Q4 Loss decreases, but misses estimates - Nasdaq
Wed, 27 Sep 2023
Pre-Market Earnings Report for September 28, 2023 : ACN, JBL ... - Nasdaq
Thu, 21 Sep 2023
Palatin Technologies, Inc. (PTN) Stock Falls -19.42% This Week: Is It a Good Pick? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
